| Identification | Back Directory | [Name]
IRBP (1-20), human | [CAS]
298202-25-2 | [Synonyms]
IRBP (1-20), human
L-Aspartic acid, glycyl-L-prolyl-L-threonyl-L-histidyl-L-leucyl-L-phenylalanyl-L-glutaminyl-L-prolyl-L-seryl-L-leucyl-L-valyl-L-leucyl-L-α-aspartyl-L-methionyl-L-alanyl-L-lysyl-L-valyl-L-leucyl-L-leucyl- | [Molecular Formula]
C101H164N24O28S | [MDL Number]
MFCD08274407 | [MOL File]
298202-25-2.mol | [Molecular Weight]
2194.59 |
| Chemical Properties | Back Directory | [Boiling point ]
2184.9±65.0 °C(Predicted) | [density ]
1.275±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
2.89±0.10(Predicted) | [color ]
White to off-white | [Sequence]
Gly-Pro-Thr-His-Leu-Phe-Gln-Pro-Ser-Leu-Val-Leu-Asp-Met-Ala-Lys-Val-Leu-Leu-Asp |
| Hazard Information | Back Directory | [Uses]
IRBP (1-20), human contains a major epitope for the H-2b haplotype. IRBP (1-20), human induces experimental autoimmune uveoretinitis (EAU) in H-2b mice[1][2]. | [in vivo]
IRBP (1-20), human TFA induces EAU[2].
For determination of proliferative and cytokine responses, lymph node and spleen cells are collected 21 days after immunization and are stimulated in culture with the appropriate antigen. Cells of C57BL/6 mice and 129/J mice immunized with IRBP (1-20), human TFA proliferated in response to the peptide[2]. | Animal Model: | C57BL/6 (H-2bb[2] | | Dosage: | 200, 300 μg | | Administration: | I.h.; After 21 days | | Result: | C57BL/6 (H-2bb) also developed disease, albeit with a lower average score than C57BL/6.
|
| [References]
[1] Avichezer D, et al. Residues 1-20 of IRBP and whole IRBP elicit different uveitogenic and immunological responses in interferon gamma deficient mice. Exp Eye Res. 2000;71(2):111‐118. DOI:10.1006/exer.2000.0860
[2] Avichezer D, Silver PB, Chan CC, Wiggert B, Caspi RR. Identification of a new epitope of human IRBP that induces autoimmune uveoretinitis in mice of the H-2b haplotype. Invest Ophthalmol Vis Sci. 2000;41(1):127‐131. PMID:10634611 |
|
|